北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京市康达律师事务所 关于北京热景生物技术股份有限公司 法律意见书 康达股会字【2025】第 0126 号 二〇二五年五月 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武 汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 法律意见书 北京市康达律师事务所 关于北京热景生物技术股份有限公司 康达股会字【2025】第0126号 致：北京热景生物技术股份有限公司 根据《中华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人民共和国证券 法》 （以下简称"《证券法》"）、 《上市公司股东大会规则》 （以下简称"《规则》"）、 《北 京热景生物技术股份有限公司章程》 （以下简称"《公司章程》"）及北京热景生物技术 股份有限公司（以下简称"公司"）与北京市康达律师事务所（以下简称"本所"）签 订的法律顾问协议，本所律师对公司 2025 年第二次临时 ...

Core Viewpoint - The medical device industry experienced a rise of 1.19% on May 12, with a net inflow of 172 million in capital, indicating positive investor sentiment towards the sector [1] Group 1: Market Performance - A total of 98 stocks in the medical device sector increased in value, while 20 stocks declined [1] - The top-performing stocks included: - Shangrong Medical (+10.0%) - Lude Medical (+7.78%) - Kaili Medical (+6.88%) - Aipeng Medical (+5.45%) - Shuoshi Biological (+5.0%) [1] Group 2: Capital Inflow - The net capital inflow for the top stocks was as follows: - Shangrong Medical: 4.8 million, 43.17% of net capital - Lude Medical: 1.99 million, 18.01% of net capital - Kaili Medical: -1.18 million, -0.43% of net capital [1] Group 3: Declining Stocks - The stocks with the largest declines included: - Rejing Biological (-5.39%) - Haooubo (-4.67%) - Kehua Biological (-4.25%) - Huitai Medical (-2.79%) - Dabao Medical (-2.04%) [1]

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 法律意见书 北京市康达律师事务所 关于北京热景生物技术股份有限公司 2025 年第二次临时股东大会的法律意见书 康达股会字【2025】第0126号 北京市康达律师事务所 关于北京热景生物技术股份有限公司 2025 年第二次临时股东大会的 法律意见书 康达股会字【2025】第 0126 号 二〇二五年五月 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 致：北京热景生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上 ...

者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 12 日 证券代码：688068 证券简称：热景生物 公告编号：2025-035 北京热景生物技术股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 （二） 股东大会召开的地点：北京市大兴区中关村科技园区大兴生物医药产业 基地庆丰西路 55 号公司三层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 236 | | --- | --- | | 普通股股东人数 | 236 | | 2、出席会议的股东所持有的表决权数量 | 28,544,004 | | 普通股股东所持有表决权数量 | 28,544,004 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 33.2917 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（ ...

A股创新药概念集体回调，迈威生物跌超10%，百济神州、信立泰双双跌超8%，益方生物、舒泰神、热 景生物、百利天恒、诺诚健华等跌幅靠前。 ...

早盘 创新药概念集体回调， 迈威生物跌超10%， 百济神州、 信立泰双双跌超8%， 益方生物、 舒泰 神、 热景生物、 百利天恒、 诺诚健华等跌幅靠前。 ...

关于公司及子公司近期获得资质情况的自愿披露 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司（以下简称"公司"）及子公司近期获得境外 资质认证 23 项。相关信息如下： 证券代码：688068 证券简称：热景生物 公告编号：2025-034 北京热景生物技术股份有限公司 | | N 末端 B | 型钠 | N-terminal Pro-B-type | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 18 | 尿肽前体测定 试剂盒（磁微 | | Natriuretic Peptide test STAT | 68-2-2-1-0004 351 | Class C | 2025/4/29 | 2029/12/31 | 泰国 | | | 粒化学发光免 疫分析法） | | (Chemiluminescence Immunoassay) | | | | | | | 19 | NT-proBNP 非 STAT-C ...

5月6日，热景生物今日收盘118.35元，下跌4.17%，最新市净率3.67，总市值109.44亿元。 截至2025年一季报，共有55家机构持仓热景生物，其中基金52家、其他3家，合计持股数2869.52万股， 持股市值27.41亿元。 北京热景生物技术股份有限公司的主营业务为紧紧围绕创新生物技术，布局从疾病的早期筛查、诊断到 治疗的解决方案。公司的主要产品为体外诊断产品、生物创新药等。 序号股票简称PE(TTM)PE(静)市净率总市值(元)12热景生物-49.73-57.303.67109.44亿行业平均 48.9047.004.53103.78亿行业中值36.4137.242.4046.92亿1天益医疗-1685.63-2887.291.8021.48亿2澳华内 镜-613.48307.694.9164.65亿3诺唯赞-417.99-494.372.2989.45亿4博晖创新-329.61523.043.5248.36亿5爱朋 医疗-325.82247.533.9226.73亿6硕世生物-125.93-1840.221.1336.84亿7奥精医疗-117.01-171.501.5421.72亿 8睿昂基因 ...

Core Insights - The Chinese innovative drug industry is experiencing a positive trend, with increasing industry prosperity and significant breakthroughs in product development by various companies [1][2][3] - The AACR annual meeting showcased the strength of Chinese innovative drug research, with 126 companies presenting nearly 300 new drug research results [2] - Several companies reported impressive financial results, indicating a recovery and growth in the sector [4][5][6] Industry Developments - The AACR meeting highlighted the growing influence of Chinese innovative drugs, with over 80 ADC studies and nearly 40 bispecific antibody studies presented [2] - Notable approvals include the new BTK inhibitor from Innovent Biologics and the PD-1/VEGF bispecific antibody from Kangfang Biotech, both receiving regulatory approval for cancer treatment [3] - The industry is seeing a trend of improved financial performance, with companies like Heng Rui Pharma reporting a 22.63% increase in revenue and a 47.28% increase in net profit [4] Financial Performance - Heng Rui Pharma achieved a revenue of 27.985 billion yuan, with a net profit of 6.337 billion yuan, reflecting strong growth [4] - Bai Li Tian Heng reported a staggering 936.31% increase in revenue to 5.823 billion yuan, turning a profit due to a significant upfront payment from a global pharmaceutical partner [4] - Shen Zhou Cell's revenue reached 2.513 billion yuan, marking a 33.13% increase, with the company achieving profitability for the first time [5] Market Catalysts - The innovative drug sector is being catalyzed by various factors, including overseas licensing, domestic policy support, and clinical data advancements [7] - Recent policies in Beijing and Shenzhen aim to accelerate innovation in the pharmaceutical industry, offering financial incentives for successful drug approvals [7] - Investment trends show a significant increase in domestic innovative drug financing, with a 51.78% year-on-year growth in March [7] Future Outlook - Industry experts believe that continued policy support will provide better development opportunities for differentiated innovative drugs in China [8] - The focus on innovation and internationalization remains a core strategy for the industry, with expectations for faster approval processes and supportive pricing mechanisms [8]

Group 1 - The core viewpoint of the news is that 热景生物 (688068.SH) has reported its Q1 2025 financial results, highlighting significant institutional investor interest and changes in shareholding patterns [1] - As of April 30, 2025, a total of 55 institutional investors hold shares in 热景生物, with a combined holding of 28.6952 million shares, representing 31.03% of the total share capital [1] - The top ten institutional investors collectively hold 23.88% of the shares, with an increase of 1.63 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 18 funds increased their holdings in this period, with a total increase rate of 3.19%, including funds like 易方达医药生物股票A and 农银医疗保健股票 [2] - Conversely, 11 funds reduced their holdings, with a decrease rate of 0.54%, including funds like 富国精准医疗灵活配置混合A and 招商景气优选股票A [2] - There were 16 newly disclosed public funds this period, while 107 funds were not disclosed compared to the previous quarter [2]